EA201990307A1 - COMPOSITIONS CONTAINING SILICON DIOXIDE NANOPARTICLES AND THEIR APPLICATION IN METHODS OF ACTIVATION OF T-LYMPHOCYTES IN THERAPY - Google Patents

COMPOSITIONS CONTAINING SILICON DIOXIDE NANOPARTICLES AND THEIR APPLICATION IN METHODS OF ACTIVATION OF T-LYMPHOCYTES IN THERAPY

Info

Publication number
EA201990307A1
EA201990307A1 EA201990307A EA201990307A EA201990307A1 EA 201990307 A1 EA201990307 A1 EA 201990307A1 EA 201990307 A EA201990307 A EA 201990307A EA 201990307 A EA201990307 A EA 201990307A EA 201990307 A1 EA201990307 A1 EA 201990307A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lymphocytes
activation
silicon dioxide
compositions containing
therapy
Prior art date
Application number
EA201990307A
Other languages
Russian (ru)
Inventor
Джонатан Джозеф Пауэлл
Нуно Хорхе Родригес Фариа
Рейчел Элейн Хьюитт
Брэдли Майкл Вис
Карлос Бастос
Original Assignee
Юнайтед Кингдом Рисерч Энд Инновейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юнайтед Кингдом Рисерч Энд Инновейшн filed Critical Юнайтед Кингдом Рисерч Энд Инновейшн
Priority claimed from PCT/EP2017/070183 external-priority patent/WO2018029247A1/en
Publication of EA201990307A1 publication Critical patent/EA201990307A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Описаны композиции, содержащие частицы диоксида кремния, имеющие средний размер, определенный стандартными способами определения размера, от 0,5 до 20 нм, для применения при активации лимфоцитов в культуре или цельной крови.Describes compositions containing particles of silicon dioxide having an average size determined by standard methods of determining size, from 0.5 to 20 nm, for use in the activation of lymphocytes in culture or whole blood.

EA201990307A 2017-02-03 2017-08-09 COMPOSITIONS CONTAINING SILICON DIOXIDE NANOPARTICLES AND THEIR APPLICATION IN METHODS OF ACTIVATION OF T-LYMPHOCYTES IN THERAPY EA201990307A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1701827.6A GB201701827D0 (en) 2017-02-03 2017-02-03 Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy
PCT/EP2017/070183 WO2018029247A1 (en) 2016-08-10 2017-08-09 Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy

Publications (1)

Publication Number Publication Date
EA201990307A1 true EA201990307A1 (en) 2019-08-30

Family

ID=58462464

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990307A EA201990307A1 (en) 2017-02-03 2017-08-09 COMPOSITIONS CONTAINING SILICON DIOXIDE NANOPARTICLES AND THEIR APPLICATION IN METHODS OF ACTIVATION OF T-LYMPHOCYTES IN THERAPY

Country Status (2)

Country Link
EA (1) EA201990307A1 (en)
GB (1) GB201701827D0 (en)

Also Published As

Publication number Publication date
GB201701827D0 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
PH12019500862A1 (en) Novel cd47 monoclonal antibodies and uses thereof
MX2019007587A (en) Ophthalmic composition for treatment of dry eye disease.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2019007480A (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation.
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EA201992546A1 (en) MEANS ON THE BASIS OF ANTIBODIES TO CD33
CY1121849T1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MA39248B1 (en) Anti-jagged1 antibodies and methods of use thereof
MX2017002085A (en) Protein/oligonucleotide core-shell nanoparticle therapeutics.
BR112017000464A2 (en) gamma delta t cells and their use
EA201592203A1 (en) METHODS OF TREATMENT OF Taupathy
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EA202191513A1 (en) REDUCING THE VISCOSITY OF PHARMACEUTICAL COMPOSITIONS
EA201992175A1 (en) COMPOSITIONS AND METHODS INCLUDING PROBIOTIC MOLECULES
WO2014145485A3 (en) Map kinase modulators and uses thereof
EA201891609A1 (en) DERIVATIVES 3 - ((HETERO-) ARYL) ALKYL-8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DECANE
EA201891611A1 (en) DERIVATIVES 3 - ((HETERO-) Aryl) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4,5] DEAN
EA201891610A1 (en) DERIVATIVES 3- (CARBOXYETHYL) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DEAN
MA39228A1 (en) Compositions for use in treating allergic conditions
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2021001361A (en) Liquid human fibrinogen composition.
EA201990307A1 (en) COMPOSITIONS CONTAINING SILICON DIOXIDE NANOPARTICLES AND THEIR APPLICATION IN METHODS OF ACTIVATION OF T-LYMPHOCYTES IN THERAPY
MX2017006491A (en) Compositions and methods for modulating at2r activity.
MA40817A (en) LONG-ACTION COMBINATION COMPOSITIONS AND METHODS FOR CONTROLLING HEPATITIS C
PH12018502139A1 (en) Phosphaplatin liquid formulations